['multiple myeloma']
['elotuzumab', 'lenalidomide', 'dexamethasone']

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2

          -  Documented evidence of active multiple myeloma:

               -  Newly diagnosed, not candidate for transplant

               -  Relapsed/refractory who have received up to 3 prior lines of therapy

          -  Prior Lenalidomide exposure is permitted only if the following criteria are fulfilled:

               -  Not refractory to prior Lenalidomide which is defined as no progression while
                  receiving Lenalidomide or within 60 days of last dose of Lenalidomide

               -  Subject did not discontinue Lenalidomide due to a Grade ≥3 related adverse event
                  (AE)

        Exclusion Criteria:

          -  Target Disease Exceptions

               -  Plasma cell leukemia

               -  Monoclonal gammopathy of undetermined significance (MGUS)

               -  Smoldering Myeloma

          -  Primary amyloidosis

          -  Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes
             (POEMS) syndrome
      